Table 1 Clinical characteristics of the patients according to ctDNA positivity at baseline
Characteristics | Overall, n (%) | ctDNA unavailable, n (%) | ctDNA positive, n (%) | ctDNA negative, n (%) | p value ctDNApos vs ctDNAneg |
|---|---|---|---|---|---|
N patients | 69 (100%) | 5 (7%) | 39 (57%) | 25 (36%) | |
Age, median (IQR) | 59 (51, 66) | 57 (51, 73) | 61 (56, 66) | 57 (47, 64) | 0.2 |
Gender | 0.5 | ||||
Male | 29 (42%) | 4 (80%) | 14 (36%) | 11 (44%) | |
Female | 40 (58%) | 1 (20%) | 25 (64%) | 14 (56%) | |
Prior number of lines of therapy | 0.05 | ||||
0 | 44 (64%) | 5 (100%) | 20 (51%) | 19 (76%) | |
≥1 | 25 (36%) | 0 (0%) | 19 (49%) | 6 (24%) | |
Baseline serum LDH, N = 68 | 0.002 | ||||
Normal | 37 (54%) | 4 (80%) | 14 (37%) | 19 (76%) | |
Elevated | 31 (46%) | 1 (20%) | 24 (63%) | 6 (24%) | |
Chromosome 3 | 0.2 | ||||
Disomy 3 | 12 (17%) | 2 (40%) | 8 (21%) | 2 (8%) | |
Loss of heterozygosity | 57 (83%) | 3 (60%) | 31 (79%) | 23 (92%) | |
Diameter of the largest metastasis according to TNM | 0.0000025 | ||||
M1a | 40 (58%) | 4 (80%) | 13 (33%) | 23 (92%) | |
M1b/c | 29 (42%) | 1 (20%) | 26 (67%) | 2 (8%) | |
Sites of metastases at tebentafusp initiation | 0.5 | ||||
Liver | 59 (86%) | 5 (100%) | 32 (82%) | 22 (88%) | |
Liver + Other | 10 (14%) | 0 (0%) | 7 (18%) | 3 (12%) | |
Best response, N = 68 | 0.002 | ||||
PD | 38 (56%) | 2 (40%) | 27 (71%) | 9 (36%) | |
PR | 7 (10%) | 0 (0%) | 0 (0%) | 7 (28%) | |
SD | 23 (34%) | 3 (60%) | 11 (29%) | 9 (36%) | |
SF3B1, N = 62 | 0.4 | ||||
No | 51 (82%) | 3 (100%) | 28 (78%) | 20 (87%) | |
Yes | 11 (18%) | 0 (0%) | 8 (22%) | 3 (13%) | |
BAP1, N = 61 | 0.2 | ||||
No | 15 (25%) | 2 (50%) | 10 (29%) | 3 (13%) | |
Yes | 46 (75%) | 2 (50%) | 24 (71%) | 20 (87%) | |
EIF1AX, N = 59 | |||||
No | 59 (100%) | 3 (100%) | 33 (100%) | 23 (100%) |
